Tempest Therapeutics, Inc. (NASDAQ:TPST – Get Free Report) saw a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 3,720,000 shares, a growth of 100.0% from the September 30th total of 1,860,000 shares. Currently, 17.6% of the shares of the stock are short sold. Based on an average trading volume of 4,310,000 shares, the short-interest ratio is currently 0.9 days.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a “buy” rating and issued a $47.00 price objective on shares of Tempest Therapeutics in a report on Thursday, October 10th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $20.75.
View Our Latest Analysis on TPST
Insiders Place Their Bets
Hedge Funds Weigh In On Tempest Therapeutics
A hedge fund recently bought a new stake in Tempest Therapeutics stock. Dimensional Fund Advisors LP purchased a new stake in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 25,084 shares of the company’s stock, valued at approximately $55,000. Dimensional Fund Advisors LP owned 0.11% of Tempest Therapeutics as of its most recent filing with the SEC. 22.52% of the stock is owned by institutional investors.
Tempest Therapeutics Price Performance
Shares of TPST stock traded up $0.03 during trading hours on Friday, reaching $1.09. The company had a trading volume of 3,577,000 shares, compared to its average volume of 2,029,640. Tempest Therapeutics has a 12-month low of $0.92 and a 12-month high of $6.00. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.17 and a current ratio of 2.17. The company has a market capitalization of $27.48 million, a price-to-earnings ratio of -0.68 and a beta of -1.86. The stock has a fifty day moving average of $1.29 and a 200-day moving average of $2.19.
Tempest Therapeutics (NASDAQ:TPST – Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.05. On average, equities analysts anticipate that Tempest Therapeutics will post -1.5 earnings per share for the current year.
About Tempest Therapeutics
Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.
Featured Stories
- Five stocks we like better than Tempest Therapeutics
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Most Volatile Stocks, What Investors Need to Know
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- What is a SEC Filing?
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.